The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 18, 2023

Filed:

Aug. 28, 2019
Applicant:

Université DE Montréal, Montreal, CA;

Inventors:

Céline Laumont, Victoria, CA;

Pierre Thibault, Montreal, CA;

Sébastien Lemieux, Lasalle, CA;

Claude Perreault, Montreal, CA;

Assignee:

UNIVERSITÉ DE MONTRÉAL, Montreal, CA;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 7/06 (2006.01); A61P 35/02 (2006.01); C07K 14/74 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C07K 7/06 (2013.01); A61P 35/02 (2018.01); C07K 14/70539 (2013.01); A61K 38/00 (2013.01);
Abstract

T cells, notably CD8 T cells, are known to be essential players in tumor eradication as the presence of tumor-infiltrating lymphocytes (TILS) in several cancers positively correlates with a good prognosis. To eliminate tumor cells, CD8 T cells recognize tumor antigens, which are MHC I-associated peptides present at the surface of tumor cells, with no or very low expression on normal cells. Described herein a proteogenomic approach using RNA-sequencing data from cancer and normal-matched mTECsamples in order to identify non-tolerogenic tumor-specific antigens derived from (i) coding and non-coding regions of the genome, (ii) non-synonymous single-base mutations or short insertion/deletions and more complex rearrangements as well as (iii) endogenous retroelements, which works regardless of the sample's mutational load or complexity.


Find Patent Forward Citations

Loading…